128 related articles for article (PubMed ID: 30322471)
1. [Recommendations of the main clinical practice guidelines].
Miravet I Jiménez S
Semergen; 2018 Jun; 44 Suppl 1():3-9. PubMed ID: 30322471
[TBL] [Abstract][Full Text] [Related]
2. [Use of dipeptidyl peptidase-4 inhibitors in patients with diabetes].
Carramiñana Barrera FC
Semergen; 2018 Jun; 44 Suppl 1():10-17. PubMed ID: 30322468
[TBL] [Abstract][Full Text] [Related]
3. [Use of dipeptidyl peptidase-4 inhibitors in diabetic patients in special situations].
Seguí Díaz M
Semergen; 2018 Jun; 44 Suppl 1():18-25. PubMed ID: 30322469
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238
[TBL] [Abstract][Full Text] [Related]
5. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.
van Baar MJB; van Ruiten CC; Muskiet MHA; van Bloemendaal L; IJzerman RG; van Raalte DH
Diabetes Care; 2018 Aug; 41(8):1543-1556. PubMed ID: 30030256
[TBL] [Abstract][Full Text] [Related]
7. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
Lau DC; Teoh H
Can J Diabetes; 2015 Dec; 39 Suppl 5():S148-54. PubMed ID: 26654858
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
9. [Type 2 diabetes mellitus: new treatments].
Ascaso JF
Med Clin (Barc); 2014 Aug; 143(3):117-23. PubMed ID: 23937815
[TBL] [Abstract][Full Text] [Related]
10. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
Gooßen K; Gräber S
Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
[TBL] [Abstract][Full Text] [Related]
12. [Incretin mimetic drugs: therapeutic positioning].
López Simarro F
Semergen; 2014 Jul; 40 Suppl 2():25-33. PubMed ID: 25311717
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
Barnett AH; Charbonnel B; Moses RG; Kalra S
Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
[TBL] [Abstract][Full Text] [Related]
14. The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies.
Molina-Vega M; Muñoz-Garach A; Fernández-García JC; Tinahones FJ
Expert Opin Drug Saf; 2018 Aug; 17(8):815-824. PubMed ID: 29975558
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.
Rosenstock J; Lewin AJ; Norwood P; Somayaji V; Nguyen TT; Teeter JG; Johnson SL; Dai H; Terra SG
Diabet Med; 2011 Apr; 28(4):464-9. PubMed ID: 21392067
[TBL] [Abstract][Full Text] [Related]
16. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Bonora E; Cigolini M
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
18. [Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2013 Sep; 68(9):479-85. PubMed ID: 24180204
[TBL] [Abstract][Full Text] [Related]
19. Alogliptin benzoate for management of type 2 diabetes.
Saisho Y
Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
[TBL] [Abstract][Full Text] [Related]
20. Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines.
Morillas C
Med Clin (Barc); 2016 Nov; 147 Suppl 1():49-53. PubMed ID: 28760226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]